Efficacy of open-label venlafaxine in subjects with major depressive disorder: Associations with neuroendocrine response to serotonergic and noradrenergic probes

Psychiatry Research

Volumn 128, Issue 2, 2004, Pages 203-206

  Grossman, Robert ^a,b   Reynolds, Dierdre ^c   Goodman, Maryanne ^a,b   New, Antonia ^a,b   Silverman, Jeremy ^a,b   Schmeidler, James ^a   Mitropoulou, Vivian ^a   Siever, Larry J ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Psychiatry   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Clonidine; Ipsapirone; Major depression; Neuroendocrine; Treatment; Venlafaxine

Indexed keywords

CLONIDINE; IPSAPIRONE; NORADRENALIN; PLACEBO; VENLAFAXINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EXPERIENCE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MECHANICAL PROBE; NEUROENDOCRINE SYSTEM; NORADRENERGIC SYSTEM; OUTPATIENT; PREDICTION; PRIORITY JOURNAL; PROVOCATION TEST; SAMPLE SIZE; SCORING SYSTEM; SEROTONINERGIC SYSTEM; SYMPTOM; TEMPERATURE;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CLONIDINE; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NOREPINEPHRINE; PERSONALITY INVENTORY; PYRIMIDINES; SEROTONIN; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 5644291962     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2004.04.005     Document Type: Article

References (7)

1. Delgado P.L., Price L.H., Heninger G.R., Charney D.S. Neurochemistry of affective disorders. Paykel E.S. Handbook of Affective Disorders. 1992;219-253 Chrurchill Livingstone, New York
2. de Montigny C., Chaput Y., Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. Journal of Clinical Psychiatry. 51(Suppl. B):1990;4-8
3. Lesch K.P., Rupprecht R., Poten B., Müller U., Sohnle K., Fritze J., Schulte H.M. Endocrine responses to 5-hydroxytryptamine-1A receptor activation by ipsapirone in humans. Biological Psychiatry. 26:1989;203-205
4. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E., Nielsen S.T., Sigg E.B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochemical Pharmacology. 35:1986;4493-4497
5. Rudolph R.L., Fabre L.F., Feighner J.P., Rickels K., Entsuah R., Derivan A.T. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Journal of Clinical Psychiatry. 59:1998;116-122
6. Siever L.J., Trestman R.L., Coccaro E.F., Bernstein D., Gabriel S.M., Owen K., Moran M., Lawrence T., Rosenthal J., Horvath T.B. The growth hormone response to clonidine in acute and remitted depressed male patients. Neuropsychopharmacology. 6:1992;165-177
7. Thase M.E. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. Journal of Clinical Psychiatry. 58:1997;393-398